Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT01689142
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT01689142
-
- Other papers using this trial's data
- New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01689142. Randomized; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2013-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
- Acronym
- EDITION JP II
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine new formulation (HOE901)
- Intervention (Drug)
- Insulin glargine (HOE901)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01689142- Content hash
b827f29b2b4973ee29dc8aee59958de80895010d06805b13621d3134b6a509c2